PULMONARY FIBROSIS

This study tests an inhaled version of the drug pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their u…

This study looks at whether using a heart-lung machine (ECMO) routinely during lung transplants is better than using it only when necessary. About 218 people getting a lung transplant will take part. The goal is to find out which approach reduces time in the ICU and improves reco…

This study tests a special PET/CT scan using a new tracer called [68Ga]Ga-NI-FAPI-04 to better see diseases linked to fibroblast activation, such as tumors, heart problems, lung scarring, and immune conditions. About 30 adults, including healthy volunteers, will get the scan to s…

This early-phase study tests a radioactive imaging agent called [68Ga]CBP8 to see if it can safely detect collagen buildup (scarring) in the lungs of people with pulmonary fibrosis and lung cancer. Researchers will compare scans from healthy volunteers and patients to see if the …

This study aims to find specific genetic traits that may explain why some people develop pulmonary fibrosis and why scarring patterns differ. Researchers will collect blood samples from 2,000 adults diagnosed with pulmonary fibrosis to analyze their DNA. The goal is to better und…

This study uses special PET and MRI scans to see how immunosuppressive drugs (like mycophenolate or prednisone) affect collagen buildup and tissue damage in the lungs of people with certain types of interstitial lung disease (ILD) that are not idiopathic pulmonary fibrosis. Resea…

This study looks at how genes play a role in lung diseases like cystic fibrosis, asthma, and pulmonary fibrosis. Researchers will study the DNA of up to 3,500 people with and without lung disease to find genetic differences. The goal is to better understand what causes these dise…

This study tests how a new experimental drug (HRS-9813) interacts with two approved medicines for pulmonary fibrosis (pirfenidone and nintedanib) in 20 healthy adults aged 18-45. The goal is to measure drug levels in the blood and check for side effects, helping to guide future d…

This study is creating a registry and biobank for people with interstitial lung diseases (ILD), including sarcoidosis and pulmonary fibrosis. Researchers will collect medical data and biological samples from up to 1,000 participants to support future studies. The goal is to bette…

This study collects lung tissue from patients awaiting a lung transplant to better understand what causes pulmonary fibrosis, a disease that scars the lungs. Researchers will examine cells and proteins in the tissue to find clues about the disease. The study does not offer any tr…

This observational study aims to find early warning signs (biomarkers) that can predict when lung scarring (fibrosis) will get worse in people with various interstitial lung diseases. Researchers will follow 450 adults with conditions like idiopathic pulmonary fibrosis (IPF) or o…

This study is testing whether special PET and MRI scans can predict how quickly lung scarring (pulmonary fibrosis) will worsen in people with certain lung diseases. Researchers will follow 60 adults for up to 2 years to see if the scans can identify who will develop progressive f…

This study looks at whether people with pulmonary fibrosis can use home monitoring and video calls instead of half their regular clinic visits. The goal is to see if this helps patients manage their own health better. About 220 adults with pulmonary fibrosis will take part, and r…